Zymeworks Inc
F:0OX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Net Margin
Zymeworks Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CA |
Z
|
Zymeworks Inc
F:0OX
|
1.2B EUR |
-156%
|
|
| IL |
C
|
Can Fite Biopharma Ltd
TASE:CANF
|
707T ILS |
-1 456%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-21 040%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
399.7B USD |
4%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
181.3B USD |
19%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
151.9B USD |
28%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
122.7B USD |
31%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-392%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
85.8B USD |
32%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
84.5B AUD |
19%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
55.7B USD |
1%
|
Zymeworks Inc
Glance View
Zymeworks Inc., a clinical-stage biopharmaceutical company, is on a mission to redefine the treatment landscape for serious diseases through its innovative approach to protein engineering and therapeutics. Established in Canada, Zymeworks is at the forefront of creating multifunctional therapeutics designed to combat cancer and other complex diseases. Central to its operation is the proprietary Azymetric™ platform, an advanced technology that enables the development of bispecific antibodies. This platform allows the creation of drugs that can simultaneously target two distinct antigens, vastly improving therapeutic efficacy and minimizing side effects. This groundbreaking technology represents a convergence of advanced science and tailored medicine, with applications that could fundamentally change patient outcomes in oncology and beyond. The business model of Zymeworks is multifaceted, involving both in-house development of therapeutic candidates and collaborative partnerships with major pharmaceutical firms. Revenue generation is primarily driven through strategic alliances, where Zymeworks licenses its technology platforms to industry giants like Merck and Eli Lilly in exchange for milestone payments, royalties, and research funding. These partnerships not only provide financial resources but also validate Zymeworks' scientific advancements and accelerate the global reach of its innovations. Additionally, Zymeworks’ pursuit of developing its own pipeline of drug candidates signifies a dual-path strategy; this not only diversifies its income streams but also positions the company as a leader in the next wave of antibody therapeutics. By effectively leveraging their technology in-house, while capitalizing on external partnerships, Zymeworks seeks to establish a lasting impact in the world of biopharmaceuticals.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Zymeworks Inc's most recent financial statements, the company has Net Margin of -156.1%.